Home   |  Contact us |                        

 

Add to favorites
Detailed contents

Pharmaceutical prices to fall Traditional Chinese medicine (TCM) protected variety specials alone

Browse the number: Date:2014-12-19 11:26

Traditional Chinese medicine in our country has a history of five thousand years, traditional Chinese medicine for its safe and effective, small side effects for the majority of patients accepted, in great demand. Varieties and have the protection of the state, and exclusive varieties of proprietary Chinese medicine enterprises, in the era of big health, consumption, more has its unique advantages. Overall reduction in medical background, but they can rely on their own advantages, protecting their own "high price".

It is understood that the current national Chinese medicine level of protection for more than 10 varieties, including yunnan baiyao yunnan baiyao powder and yunnan baiyao capsule, tablet seed Huang, wuhan jianmin dragon bones negundo particles, tongrentang on palace bezoar bolus, LeiYun nightfall pellets, the company, Shanghai and yellow pharmaceutical heart of musk pills, etc.

17, at a state council executive meeting to deploy the priorities for the next stage, meeting requirement actively expand domestic effective demand, improve consumption policies, at the same time vigorously ensuring and improving people's livelihood, gradually eliminate worries about the masses pension, medical, etc. In the pharmaceutical industry, the high quality Chinese medicine in promoting health, consumption, is showing a strong growth trend.

Under the above background, as the population ages, the medicine capacity, serious illness insurance guarantee improved steadily, with first class or second class state protection and confidentiality of varieties of Chinese patent medicine listed company, is expected to be into the category of "consumption". In addition, although some proprietary Chinese medicine exist price expectations this year, but to protect the species (national secrecy varieties) price is relatively "maverick".

According to the warburg, huatai and fortis haitong, HSBC jin letter fund announced a quarterly results, at the early stage of the holdings of the fund gains higher shares at the same time, affected by the policy financial and liquor is increased for medicine, automobile, environmental protection and TMT industries configuration.

"Consumption", "great health" industry development rapidly

The rapid development of big health industry is becoming a highlight of our country medicine industry. According to the Chinese health care chamber of commerce, vice President liu zhang, health industry scale in China in 2013 is expected to close to 2 trillion yuan. Has the national protection species, as well as exclusive varieties of proprietary Chinese medicine enterprises, in the era of big health, consumption, more unique advantages.

Out the survey, 1 to 2 months of this year, Chinese traditional medicine industry has a higher growth rate. Among them, Chinese medicine yinpian profit growth of 64%, and beyond the level of the industry over the same period.

Industry researcher said that traditional Chinese medicine in China has a strong consumer base, follow the market pricing for part of traditional Chinese medicine resources create the objective conditions, more important is the concept of traditional Chinese medicine "cure not ill", subjectively promoted gradually become an important part of high-end medical market of traditional Chinese medicine.

The international health exhibition held in Shanghai in March, over-the-counter proprietary Chinese medicine become a mainstream consumer. According to the reporter, the scene of the best selling drugs more than 95% belong to the domestic well-known production enterprise, one hundred years old, zhong xin tong ren tang pharmaceutical LeRenTang well-known pharmaceutical companies such as product our price higher than the same products, but still the most popular.

It is understood that because of the state secrecy varieties and drug production enterprise with independent pricing power, the advantages of the patent protection, therefore, the state secrecy varieties, especially can enjoy long-term confidential the secret level drugs was coveted by many drug companies.

"National support traditional Chinese medicine enterprises is consistent attitude. Many domestic cheap western medicine are generic drugs, there is no previous research and development, the traditional drug firms mostly are their research and development, the early stage of the investment is very big, so the state to protect its price advantage, that drug companies can back to this in 8 to 10 years, it has developed enthusiasm." The researchers told reporters.

It is understood that the current national Chinese medicine level of protection for more than 10 varieties, including yunnan baiyao yunnan baiyao powder and yunnan baiyao capsule, tablet seed Huang, wuhan jianmin dragon bones negundo particles, tongrentang on palace bezoar bolus, LeiYun nightfall pellets, the company, Shanghai and yellow pharmaceutical heart of musk pills, etc.

The primary varieties of traditional Chinese medicines, the unique product efficacy and strong marketing strategy, constantly create new miracles. Piece of seed Huang, for example, the company exclusive production of proprietary Chinese medicine seed Huang, its prescription, process were classified as state secret, varieties under grade 1 protection for traditional Chinese medicine. Since 2005, slice Huang year rose 10 times, established in 2012, led a stock exceeds one hundred yuan of traditional Chinese medicine.

Confidential variety advantages

Entering the second quarter of 2013, proprietary Chinese medicine price expectations to be hung on the blade of the dharma of Chris. For the national Chinese medicine confidential variety, but could be lenient. According to the reporter, in line with the second prize of national science and technology secret of an enterprise, can at least 5% less than common proprietary Chinese medicine.

Recently, the association of traditional Chinese medicine (TCM) in Beijing held an internal meeting. Development and reform commission, the price department sources said at the meeting, about this year's proprietary Chinese medicine price adjustment, again clear separate pricing, quality, emancipate the mind, seeking truth from facts. At the same time, the reporter understands, the national departments concerned about Chinese traditional medicine price adjustment this year, has held two price hearing, fully understand the opinion of the enterprise.

For many years in a Chinese medicine listed company as a marketing director Mr. Dong told reporters, whether medicare drug bidding, or basic drug bidding starting in 2009, the exclusive varieties of Chinese traditional medicine, first class or second class protected varieties of traditional Chinese medicines, almost all have no price cut, part of the marketing, public relations ability of drug companies, not only does not reduce the price, some even start to raise prices.

So far, as the drug bid news gradually, traditional Chinese medicine (TCM) policy headwinds as the "cloud" expected to be dispersed. Beijing recently released 2012 drug bidding results, are showing a "clear", Beijing won the bid price than the current basic medicines procurement prices fell about 26%, and traditional Chinese medicine (TCM) sole variety reduction of only 1%, well below market expectations.